Chicago, IL, United States
Chicago, IL, United States

Rush University Medical Center is a 676-bed academic medical center that includes hospital facilities for adults and children. It also includes the Johnston R. Bowman Health Center . It is affiliated with Rush University. Rush is a not-for-profit health care, education and research enterprise comprising Rush University Medical Center, Rush University, Rush Oak Park Hospital and Rush Health. Rush University is home to one of the first medical colleges in the midwest and includes one of the nation's top-ranked nursing colleges, as well as graduate programs in allied health, health systems management and biomedical research. Rush also offers more than 70 residency and fellowship programs in medical and surgical specialties and subspecialties. Rush is the largest non-governmental employer on Chicago's West Side and is the 20th largest private sector employer in Chicago, with more than 8,000 employees and a payroll of more than $500 million. Wikipedia.


Time filter

Source Type

Patent
Rush University Medical Center | Date: 2016-08-29

The present invention generally relates to systems and methods of treating microbial growth on a conducting surface, for example, the conducting surface of an implanted medical device. One embodiment of the method includes applying a electrical current through the conducting surface and a counter electrode. The electrical current is varied such that an electrical potential of the conducting surface alternates compared to the electrical potential of a reference electrode and where the electrical current is varied to an extent sufficient to reduce or prevent microbial growth on the conducting surface.


Patent
Rush University Medical Center | Date: 2017-02-15

Footwear including a flexible sole having a series of flexure zones positioned to correspond to primary joint axes of the human foot approximating the characteristics of a bare foot in motion.


Patent
Rush University Medical Center | Date: 2015-06-19

Fusion peptides and methods of inhibiting GrB-EHITSN or a fragment thereof are provided. The fusion peptides include an NPF peptide and a cell-permeable peptide operably connected thereto. Fusion peptides and methods of inhibiting activity of GrB-EHITSN or fragment thereof are provided. An aspect includes a fusion peptide comprising an isolated NPF peptide comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 2 and a cell-permeable peptide operably connected to the isolated NPF peptide, wherein the fusion peptide inhibits activity of GrB-EHITSN or a fragment thereof.


Patent
Rush University Medical Center | Date: 2016-12-21

A device and methods for treating an aneurysm includes a catheter capable of insertion into a body to be positioned adjacent the aneurysm, the catheter including a distal end and an operator end opposite the distal end. The catheter forms a circular pathway extending between the distal end and the operator end. A partitioner extends through the pathway of the catheter, the partitioner being rotatable within the catheter and including one or more lumens that provide an orifice from a first end of the partitioner to a second end of the partitioner. The device further includes a first coil extending through the partitioner from the first end to the second end in a first lumen and a second coil extending through the partitioner from the first end to the second end in a second lumen. The first and second lumens may be fully circumscribed by the partitioner and have first and second diameters, respectively.


Patent
Rush University Medical Center | Date: 2017-01-05

A kit and/or method for use during surgery is configured to decrease the risk of accidental retention of foreign objects, such as surgical items or medical devices, used in surgery inside of a patient after the surgery is completed. Specifically, illustrative kits may include, but not be limited to, a combination of one or more foreign objects, an anchoring member attached to a point outside of the patient or surgical field, and at least one or more connection members connecting the foreign objects to the anchoring member. Illustrative methods may include, but not be limited to, anchoring one or more foreign object by one or more connection members, wherein a first end of each connection member is attached to the foreign object, and a second end of each connection member is attached to a junction member; attaching the junction member to an anchoring member; and attaching the anchoring member to a structure that is outside the patient or surgical field.


Patent
Rush University Medical Center | Date: 2016-11-28

The disclosure provides pharmaceutical compositions including an oligonucleotide that down-regulates the over-expression of at least one miRNA of SEQ ID NOs: 1-283. The oligonucleotide may be complementary to the nucleotide sequence of at least one of SEQ ID NOs: 1-283, or hybridizes under stringent conditions to a nucleotide sequence of at least one of SEQ ID NOs: 1-283. Further provided are methods of diagnosing Parkinsons Disease (PD) in a subject. The methods may include detecting the level of expression of at least one miRNA of SEQ ID NOs: 1-283 in a biological sample from the subject, and comparing the level of expression in the sample to the level of expression in a reference. Further provided are methods for treating, preventing, or reducing the risk of PD. Kits are also provided.


Patent
Rush University Medical Center and University of Illinois at Urbana - Champaign | Date: 2016-11-28

Disclosed herein are compounds and compositions useful for reducing the risk of infection. In particular, disclosed herein are mandelic acid condensation polymers, compositions comprising such compounds, processes for producing such compounds, and methods of using such compounds.


Patent
Rush University Medical Center | Date: 2017-05-03

Fusion peptides and methods of inhibiting GrB-EHITSN or a fragment thereof are provided. The fusion peptides include an NPF peptide and a cell-permeable peptide operably connected thereto. Fusion peptides and methods of inhibiting activity of GrB-EHITSN or fragment thereof are provided. An aspect includes a fusion peptide comprising an isolated NPF peptide comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 2 and a cell-permeable peptide operably connected to the isolated NPF peptide, wherein the fusion peptide inhibits activity of GrB-EHITSN or a fragment thereof.


Patent
Rush University Medical Center | Date: 2017-03-22

Methods of treating kidney disease and protecting podocytes from injury are provided. Methods of screening agents for the treatment of kidney disease are also provided. In addition, methods of identifying structural or functional defects in a patients podocytes and methods of identifying kidney disease causing agents in a patients biological sample are also provided.


DeCoursey T.E.,Rush University Medical Center
Physiological Reviews | Year: 2013

Voltage-gated proton channels (HV) are unique, in part because the ion they conduct is unique. HV channels are perfectly selective for protons and have a very small unitary conductance, both arguably manifestations of the extremely low H+ concentration in physiological solutions. They open with membrane depolarization, but their voltage dependence is strongly regulated by the pH gradient across the membrane (ΔpH), with the result that in most species they normally conduct only outward current. The HV channel protein is strikingly similar to the voltage-sensing domain (VSD, the first four membrane-spanning segments) of voltage-gated K+ and Na+ channels. In higher species, HV channels exist as dimers in which each protomer has its own conduction pathway, yet gating is cooperative. HV channels are phylogenetically diverse, distributed from humans to unicellular marine life, and perhaps even plants. Correspondingly, HV functions vary widely as well, from promoting calcification in coccolithophores and triggering bioluminescent flashes in dinoflagellates to facilitating killing bacteria, airway pH regulation, basophil histamine release, sperm maturation, and B lymphocyte responses in humans. Recent evidence that hHV1 may exacerbate breast cancer metastasis and cerebral damage from ischemic stroke highlights the rapidly expanding recognition of the clinical importance of hHV1. © 2013 the American Physiological Society.

Loading Rush University Medical Center collaborators
Loading Rush University Medical Center collaborators